Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06511882
Title Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST